Related Experiment Videos
Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists
1School of Medicine in New Orleans, Louisiana State University Medical Center, New Orleans, USA.
Insights
Hypertension can cause left ventricular hypertrophy (LVH), increasing cardiovascular risk. Blocking T-type calcium channels may help prevent or reverse this cardiac remodeling, offering a potential therapeutic strategy.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Pharmacology
Background:
- Sustained hypertension leads to cardiovascular structural changes, including left ventricular hypertrophy (LVH), a strong predictor of adverse outcomes.
- LVH is associated with increased myocardial mass and predicts myocardial infarction, stroke, and cardiovascular death in hypertensive patients.
- Preventing or reversing hypertensive LVH is a key therapeutic goal, though underlying molecular mechanisms remain unclear.
Purpose of the Study:
- To investigate the role of T-type calcium channels in cardiovascular remodeling associated with hypertension.
- To explore the potential of T-type calcium channel blockade as a therapeutic strategy for preventing or reversing LVH.
- To assess the antiproliferative effects of mibefradil, a selective T-type calcium channel blocker, in experimental models and patients with LVH.
Main Methods:
- Review of existing literature on cardiovascular remodeling in hypertension.
- Examination of experimental models demonstrating the effects of T-type calcium channel blockade.
- Analysis of clinical data on mibefradil's impact on left ventricular mass index in patients with LVH.
Main Results:
- T-type calcium channel blockade with mibefradil showed antiproliferative effects in renal and cardiac vasculature in experimental models.
- In patients with LVH, mibefradil treatment led to a reduction in the left ventricular mass index.
- These findings suggest a potential role for T-type calcium channels in the development of hypertensive cardiac remodeling.
Conclusions:
- Blockade of T-type calcium channels may represent a novel approach for the prevention or regression of cardiovascular remodeling in hypertension.
- Further research is necessary to fully elucidate the clinical implications and therapeutic potential of targeting T-type calcium channels for LVH.
- Understanding the molecular mechanisms underlying T-type calcium channel's role in remodeling could lead to more targeted antihypertensive therapies.
Abstract:
Increased myocardial mass (cardiac hypertrophy, left ventricular hypertrophy [LVH]) is an example of the widespread structural cardiovascular changes, often referred to as remodeling, that may be present in association with sustained high blood pressure. LVH strongly predicts myocardial infarction, stroke, and cardiovascular death in patients with hypertension. As a result, prevention or reversal of hypertensive LVH is widely accepted as a desirable therapeutic goal. Although the molecular mechanisms responsible for remodeling are unclear, it is believed that mechanical, endocrine, paracrine, and autocrine factors control the remodeling process. Certain antihypertensive drugs may have particularly favorable long-term effects in that they prevent and correct these structural changes in addition to reducing arterial pressure. However, the mechanism by which they achieve these effects is not well understood. It is theorized that angiotensin-converting enzyme inhibitors do so by preventing the generation of growth-promoting/mitogenic peptides and that beta-blockers interfere with the growth-promoting effects of catecholamines. In experimental models, the selective blockade of T-type calcium-ion (Ca2+) channels with mibefradil has been demonstrated to have antiproliferative effects in both the renal and cardiac vasculature; in patients with LVH, mibefradil reduced the left ventricular mass index. Therefore, blockade of T-type Ca2+ channels may be useful in the prevention or regression of cardiovascular remodeling. However, further research will be required before the clinical implications of these findings can be assessed.